Next Generation DNA Sequencing technologies are facilitating new approaches for drug discovery and development. The promise of DNA sequencing as a tool to understand disease, as well as other fundamental biological problems, established this need for new DNA sequencing technologies that could deliver more information, in a shorter time period, for less money. In 2005, 454 Life Sciences commercialized the first new, or ‘next generation’ sequencing technology.
Next Generation DNA Sequencing technology is described as next generation because it has reduced the cost of DNA sequencing over conventional Sanger sequencing by at least 10-fold while reducing the time to complete a typical project by 100-fold. In addition to improving efficiency, the massively parallel sequencing of hundreds of thousands of individual DNA molecules facilitates projects that were previously impossible with Sanger Next Generation DNA Sequencing technology.
The application of high throughput, highly parallelised next generation sequencing has been at the forefront of many recent advances in RNAi research. These technologies allow for the deeper understanding of the population of small RNAs expressed in a given tissue or cell type. These applications have lead to identification of novel mechanisms of small or microRNA synthesis as well as the discovery of novel classes of small RNAs. Since 2005, when the first next generation sequencing system was introduced.
The application of next generation sequencing to HIV research is extremely powerful because the virus rapidly mutates as a part of its normal biology. The massive throughput enabled by these platforms has allowed researchers to dig deeply into the metagenome of a viral population and identify all subtypes of virus present. The ability to sequence a viral genome thousands of times on a single sequencing run makes them an ideal tool for anti-viral research.
Integration of DNA sequencing and Next Generation DNA Sequencing into the drug discovery process will allow the identification of specific patient populations as well as identifying diagnostic and/or theranostic markers. DNA sequencing offers the most reliable and accurate method of grouping individuals into characteristic genetic profiles. Sequencing of disease-associated regions enables the differentiation of genetic profiles, regardless of the underlying genetic changes. Up until now, DNA sequencing has been of limited use in clinical trials because of the prohibitive cost and amount of time associated with sequencing the hundreds of individuals enrolled in a single trial in Next Generation DNA Sequencing technology.
Next Generation DNA Sequencing technology is described as next generation because it has reduced the cost of DNA sequencing over conventional Sanger sequencing by at least 10-fold while reducing the time to complete a typical project by 100-fold. In addition to improving efficiency, the massively parallel sequencing of hundreds of thousands of individual DNA molecules facilitates projects that were previously impossible with Sanger Next Generation DNA Sequencing technology.
The application of high throughput, highly parallelised next generation sequencing has been at the forefront of many recent advances in RNAi research. These technologies allow for the deeper understanding of the population of small RNAs expressed in a given tissue or cell type. These applications have lead to identification of novel mechanisms of small or microRNA synthesis as well as the discovery of novel classes of small RNAs. Since 2005, when the first next generation sequencing system was introduced.
The application of next generation sequencing to HIV research is extremely powerful because the virus rapidly mutates as a part of its normal biology. The massive throughput enabled by these platforms has allowed researchers to dig deeply into the metagenome of a viral population and identify all subtypes of virus present. The ability to sequence a viral genome thousands of times on a single sequencing run makes them an ideal tool for anti-viral research.
Integration of DNA sequencing and Next Generation DNA Sequencing into the drug discovery process will allow the identification of specific patient populations as well as identifying diagnostic and/or theranostic markers. DNA sequencing offers the most reliable and accurate method of grouping individuals into characteristic genetic profiles. Sequencing of disease-associated regions enables the differentiation of genetic profiles, regardless of the underlying genetic changes. Up until now, DNA sequencing has been of limited use in clinical trials because of the prohibitive cost and amount of time associated with sequencing the hundreds of individuals enrolled in a single trial in Next Generation DNA Sequencing technology.
